TruScreen Announces Initial Zimbabwe Order

14 September 2018
NZX Announcement

TruScreen HIV African Initiative Update

Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) (“Truscreen”) advises
that, following on from its deliberations with senior African health officials as announced on 27
August 2018 it has now received an initial order to the value of approximately NZ$450,000 from the
National Aids Council of Zimbabwe to supply cervical cancer screening systems (“systems”). It is
expected that the order will be completed within 30 days.
The Truscreen cervical cancer screening systems will be used in Stage 1 of a pilot program to provide
cervical cancer screening to HIV affected women in Zimbabwe.
Deliberations to supply further systems to the National Aids Council of Zimbabwe are continuing.
There are over 720,000 HIV affected women in Zimbabwe, and 13 million HIV affected women in
Africa, and these women are 6 times more likely to suffer from cervical cancer than other women.
TruScreen chair, Robert Hunter, said “This pilot program is the first step in our strategy to bring
advanced cervical cancer screening methods to the women of Africa, and in particular to the 13 million
HIV affected women in Africa. TruScreen is the ideal solution to provide cervical cancer screening to
these women, and to other women in other region who do not have access to traditional laboratory
dependant screening methods”


ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.